Abstract
Cancer stromal targeting (CAST) therapy has the potential to overcome drug resistance and improve therapeutic efficacy, even in cancer with abundant stroma that inhibits the penetration of anticancer agents. Many types of cancer form varying degrees of stroma, which generally increases with disease progression. Noninvasive imaging methods for assessing the degree of stroma formation in individual cancers are useful for diagnosing malignancy potential and selecting patients who could potentially benefit from CAST therapy. Antibodies against several types of stromal targets, including insoluble fibrin and tissue factor, have been developed and could be good candidate platforms – not only for CAST therapy, but also for imaging to assess the degree of cancer stroma formation. This section focuses primarily on antibody-based nuclear medicine imaging targeting cancer stroma because it has the highest sensitivity and quantitative ability among the noninvasive imaging techniques applicable to clinical practice, and CAST therapy has been based on antibody-drug conjugates.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
